Supplementary Figures S1-S5 from Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma

Supplementary Figures S1-S5. Loss of sorafenib resistance in vitro and during transfer of resistant tumor fragments (S1); Sorafenib plasma levels declined in early progressors (S2); Impact of tumor free-mouse treatment on tissue sorafenib metabolite levels and resistance development (S3); Additional effects of dose escalation (S4); Effects of sorafenib treatment on cell signaling pathways in tissues (S5).